R&D

While a rumoured takeover by Merck & Co has yet to materialise, Seagen is getting on with its

Lava fires up a $700m cancer licensing deal with Seagen

https://pharmaphorum.com/news/lava-fires-up-a-700m-cancer-licensing-deal-with-seagen/

Pfizer, Sangamo resume haemophilia gene therapy trial

Phil Taylor BioMarin Pharmaceuticals, gene therapy, Haematology, haemophilia, haemophilia A, Pfizer, Sangamo Therapeutics 0 Comment

Pfizer and Sangamo have restarted recruitment of patients into their registration trial for haemophilia A gene therapy giroctocogene

Pfizer, Sangamo resume haemophilia gene therapy trial

https://pharmaphorum.com/news/pfizer-sangamo-resume-haemophilia-gene-therapy-trial/

News/ R&D/ Views & Analysis/ Views and analysis

Lilly’s Mounjaro wins latest head-to-head battle in clinical trials of diabetes treatments

mike.hammerton@pharmaphorum.com clinical trial, competition, Diabetes, injections, Lilly, Mounjaro, Novo Nordisk, treatment 0 Comment

Diabetes is one of the most common health conditions in the United States, afflicting more than 11% of

Lilly’s Mounjaro wins latest head-to-head battle in clinical trials of diabetes treatments

https://pharmaphorum.com/views-and-analysis/lillys-mounjaro-wins-latest-head-to-head-battle-in-clinical-trials-of-diabetes-treatments/

AstraZeneca plant. AstraZeneca has been working on a vaccine for the Coronavirus, COVID and COVID-19.

News/ News/ R&D

AZ and Ionis’ PCSK9 cholesterol drug will not move to phase 3

Phil Taylor Amgen, AstraZeneca, cholesterol, Ionis Pharmaceuticals, Leqvio, Novartis, PCSK9 inhibitors, Praluent, Regeneron, Repatha, Sanofi 0 Comment

AstraZeneca has taken the decision not to move a PCSK9-targeting antisense drug licensed from Ionis into a phase

AZ and Ionis’ PCSK9 cholesterol drug will not move to phase 3

https://pharmaphorum.com/news/az-and-ionis-pcsk9-cholesterol-drug-will-not-move-to-phase-3/

News/ News/ News/ R&D/ Sales and Marketing

Revamped Novartis highlights top R&D programmes at management update

Phil Taylor iptacopan, Kisqali, Novartis, Pluvicto, R&D, remibrutinib, Sales and Marketing, Scemblix, strategy 0 Comment

With a reorganisation of Novartis now nearing completion, the Swiss pharma group is laying out its plans for

Revamped Novartis highlights top R&D programmes at management update

https://pharmaphorum.com/news/revamped-novartis-highlights-top-rd-programmes-at-management-update/

Helping to support momentum on antimicrobial innovation

News/ News/ R&D

Undeterred by FDA setback, GSK snaps up Spero antibiotic

Phil Taylor antibiotic, antimicrobial resistance, fda, GSK, licensing, regulatory, Spero Therapeutics, tebipenem 0 Comment

GSK is paying $66 million upfront to license rights to Spero Therapeutics novel antibiotic tebipenem Hbr, unswayed by

Undeterred by FDA setback, GSK snaps up Spero antibiotic

https://pharmaphorum.com/news/undeterred-by-fda-setback-gsk-snaps-up-spero-antibiotic/

News/ News/ R&D

Biogen trumpets data from ALS trial as FDA decision looms

Phil Taylor amyotrophic lateral sclerosis, antisense drugs, Biogen, motor neurone disease, neurology, rare disease, tofersen 0 Comment

After a torrid couple of years, Biogen can be forgiven for making the most of new data on

Biogen trumpets data from ALS trial as FDA decision looms

https://pharmaphorum.com/news/biogen-trumpets-data-from-als-trial-as-fda-decision-looms/

News/ News/ News/ Oncology/ R&D

First human data backs Calibr/AbbVie’s “switchable” CAR-T therapy

Phil Taylor AbbVie, Calibr, CAR-T therapy, immuno-oncology, Oncology, R&D 0 Comment

California biotech Calibr and partner AbbVie have reported the first clinical data on a new CAR-T technology, which

First human data backs Calibr/AbbVie’s “switchable” CAR-T therapy

https://pharmaphorum.com/news/first-human-data-backs-calibr-abbvies-switchable-car-t-therapy/

News/ R&D/ Views & Analysis/ Views and analysis

Reconfiguring COVID and influenza vaccines for long-term effectiveness

Jessica Hagen COVID-19, flu, influenza, nucleoprotein, oligoDOM, Osivax, T-cells, technology, vaccines, viruses 0 Comment

Alexandre Le Vert, CEO and co-founder of Osivax, discusses the company’s breakthrough vaccine technology, oligoDOM, and how it’s

Reconfiguring COVID and influenza vaccines for long-term effectiveness

https://pharmaphorum.com/r-d/reconfiguring-covid-and-influenza-vaccines-for-long-term-effectiveness/

1 2 3 4 ›»

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com

Trending

R&D

Login